01
The rules we follow
Texas Medical Board, 22 TAC 169.25 to 169.28 (effective January 9, 2025). Injecting for cosmetic purposes and using a prescription device are the practice of medicine. Before treatment a physician, PA or APRN establishes the practitioner-patient relationship (the good faith exam) and tells the patient who will perform the procedure. The delegating physician's name and Texas license number are posted in every public area and treatment room. TMB's February 2025 bulletin says advertising should carry the supervising physician's name. We put it on the site and in the ads. Jenifer's Law (Occupations Code Chapter 172, effective September 1, 2025) adds that elective IVs are ordered only by a PA or APRN and given only by a PA, APRN or RN.
Texas advertising, Occupations Code 101.201 and 22 TAC 164.3. No "unjustified expectation about the results," no confusion about credentials, models labeled, "free" must be free, "board certified" only for ABMS, AOA or TMB-approved boards, no "board eligible." The statute also names testimonials; Austin clinics run them, and we get counsel's sign-off first.
FDA. Botox Cosmetic is approved for glabellar, lateral canthal and forehead lines; "FDA-approved" on a lip-flip or masseter page implies an approval that doesn't exist. Devices are "cleared." On September 9, 2025 the FDA posted more than 50 warning letters, including to Hims & Hers, over compounded GLP-1 claims like "same active ingredient as Ozempic." Compounded drugs are never "generic," "the same as" or "FDA-approved." Compounded hormone pellets are not FDA-approved, and "natural," "safer" and "no side effects" are the claims regulators target.
FTC. Health claims need competent and reliable scientific evidence. The weight-loss "gut check" claims (two pounds a week without diet or exercise, permanent loss) are out. In July 2025 NextMed settled over "lose 53 pounds" claims and a monthly price that excluded the drug. Atypical results need the typical result disclosed; "results may vary" alone is not enough (16 CFR 255). No fake, bought or employee reviews (16 CFR 465).
HIPAA, Google and Meta. Pixels on intake forms and booking flows need a BAA or come off. Google: no advertiser-built audiences for injectables; prescription drug terms restricted. Meta: cosmetic and weight-loss ads to 18+ only, no "statements of inferiority about physical appearance," before-and-afters currently allowed for cosmetic procedures (we recheck before each launch because the rule has moved).